Precigen is up 26.3% today following a positive market reaction to the company's updated outlook for its flagship therapy, PAPZIMEOS. Although the company reported a Q4 revenue miss after the market closed yesterday, investors are focusing on the forward-looking guidance provided in the same release, which projects Q1 2026 revenue to exceed $18 million as the launch of PAPZIMEOS accelerates with broad U.S. payer coverage. This growth narrative appears to be overriding the previous quarter's financial results, as traders shift their attention to the rapid commercialization momentum of the only FDA-approved treatment for adults with RRP.
No significant catalyst events detected.